ERBB2 and breast cancer: The mechanism of abnormal activation of the PAM pathways in breast cancer includes variations in key molecules, such as amplification or overexpression of RTKs (e.g., HER2/ERBB2) and KRAS (kirsten rat sarcoma viral oncogene) mutation [26].